➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Express Scripts
Johnson and Johnson
Moodys
AstraZeneca

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,596,107

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,596,107 protect, and when does it expire?

Patent 10,596,107 protects LOTEMAX SM and is included in one NDA.

This patent has thirteen patent family members in twelve countries.

Summary for Patent: 10,596,107
Title:Ophthalmic suspension composition
Abstract: A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having D.sub.v90<5 .mu.m and D.sub.v50<1 .mu.m. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.
Inventor(s): Shawer; Mohannad (Lexington, MA), Phillips; Eric (Ontario, NY), Coffey; Martin J. (Buffalo Grove, IL)
Assignee: Bausch & Lomb Incorporated (Rochester, NY)
Application Number:15/006,525
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,596,107
Patent Claim Types:
see list of patent claims
Use; Formulation;

Recent additions to Drugs Protected by US Patent 10,596,107

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Bausch And Lomb Inc LOTEMAX SM loteprednol etabonate GEL 208219 Feb 22, 2019 RX Yes   Start Trial Y   Start Trial U-2764 TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 10,596,107

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch And Lomb Inc LOTEMAX SM loteprednol etabonate GEL;OPHTHALMIC 208219-001 Feb 22, 2019 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,596,107

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2016211745   Start Trial
Brazil 112017016016   Start Trial
Canada 2975106   Start Trial
China 107427464   Start Trial
European Patent Office 3250185   Start Trial
European Patent Office 3470059   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Harvard Business School
AstraZeneca
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.